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Background: The antiepileptic lamotrigine is approved for maintenance treatment
of bipolar disorder and augmentation therapy in treatment-resistant depression.
Previous preclinical investigations showed lamotrigine antidepressant-like eﬀects
without addressing its possible activity on motivational aspects of anhedonia, a
symptom clinically associated with poor treatment response and with blunted
mesolimbic dopaminergic responsiveness to salient stimuli in preclinical models.
Thus, in rats expressing a depressive-like phenotype we studied whether repeated
lamotrigine administration restored behavioral responses to aversive and positive
stimuli and the dopaminergic response to sucrose in the nucleus accumbens shell
(NAcS), all disrupted by stress exposure.
Methods: Depressive-like phenotype was induced in non-food-deprived adult male
Sprague-Dawley rats by exposure to a chronic protocol of alternating unavoidable
tail-shocks or restraint periods. We examined whether lamotrigine administration
(7.5 mg/kg twice a day, i.p.) for 14e21 days restored a) the competence to
escape aversive stimuli; b) the motivation to operate in sucrose self-
administration protocols; c) the dopaminergic response to sucrose consumption,.e00849
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
y-nc-nd/4.0/).
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32,000 (DARPP-32) in the NAcS, by immunoblotting.
Results: Lamotrigine administration restored the response to aversive stimuli and
the motivation to operate for sucrose. Moreover, it reinstated NAcS DARPP-32
phosphorylation changes in response to sucrose consumption.
Limitations: The pro-motivational eﬀects of lamotrigine that we report may not
completely transpose to clinical use, since anhedonia is a multidimensional
construct and the motivational aspects, although relevant, are not the only
components.
Conclusions: This study shows antidepressant-like and pro-motivational eﬀects of
repeated lamotrigine administration in a rat model of depressive symptoms.
Keywords: Neuroscience, Psychiatry, Pharmaceutical science
1. Introduction
Lamotrigine is a widely used antiepileptic agent with a broad spectrum of anticon-
vulsant eﬃcacy that is approved by the FDA and EMA for maintenance treatment of
bipolar disorder without an indication for acute mania [1, 2, 3]. It is particularly
eﬀective for the prevention of bipolar depression relapse [4, 5, 6, 7, 8, 9] and recent
guidelines recommend lamotrigine as the ﬁrst-line treatment for mild to moderate
bipolar depression [10]. Moreover, it is also used in treatment-resistant unipolar
depression as an augmentation drug and in post-traumatic stress disorder [11, 12,
13].
When the ﬁrst clinical studies indicated lamotrigine eﬃcacy in the treatment of bi-
polar depression [4, 9, 14], rodent studies were carried out in order to verify its ef-
fects in tests for antidepressant activity and models of aﬀective disorders.
Antidepressant-like eﬀects of lamotrigine have been reported after acute treatment
in the forced swimming test (FST) in mice and rats [15, 16] or after sub-chronic
administration in the learned helplessness model [16]. After long-term administra-
tion, lamotrigine shows antidepressant-like activity in rats in the maternal
deprivation-induced model [17], and in the chronic unpredictable stress model,
where it positively aﬀects performance in the FST and tail suspension test, the su-
crose preference test, and the novelty-suppressed feeding test [18].
Although the anticonvulsant eﬀects of lamotrigine are most likely related to the in-
hibition of voltage-sensitive sodium channels [19, 20], cellular and animal studies
suggest that it may modulate monoaminergic systems [15, 21, 22, 23] and may exert
neuroprotective eﬀects by reducing oxidative stress [24]. However, it is still unclear
which of these molecular mechanisms are relevant for lamotrigine eﬃcacy in the
treatment and prevention of bipolar depression [25]. Some studies support anon.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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the behavioral antidepressant-like eﬀects of lamotrigine [16, 17, 18]. Other evi-
dences suggest that lamotrigine’s mood stabilizing eﬃcacy may be related to the
enhancement of the hyperpolarization-activated inward current Ih [26]. This current
plays an important role in modulating the excitability of ventral tegmental area
(VTA) dopamine neurons, speciﬁcally the VTA dopaminergic neurons projecting
to the nucleus accumbens (NAc) [27]. In the chronic social defeat stress model
the antidepressant-like eﬀects of lamotrigine have been ascribed to its ability to regu-
late VTA dopamine neuron excitability through an increase in Ih current [27].
Anhedonia, deﬁned as loss of interest or pleasure in previously pleasurable activities,
is a core symptom of depression [28] that occurs in half of the patients with bipolar
depression [29] and has been associated with poor treatment response [30, 31].
Anhedonia may be considered as a composite symptom that can be resolved in
diﬀerent components: a reduction in the experience of pleasure (liking), a deﬁcit
in the motivation to obtain a reward (wanting), and, possibly, a disruption in reward
learning [32]. The lack of motivation (motivational anhedonia) may reﬂect an under-
lying dysfunction in dopaminergic reward circuit that originates in the VTA and pro-
jects to the NAc, a key brain region in the ventral striatum that integrates diﬀerent
excitatory and inhibitory inputs to signal the salience of stimuli [33]. Previous
studies of lamotrigine eﬀects in animal models of depression have only explored
the consummatory aspect of anhedonia by the sucrose preference test. Thus, we
aimed to investigate whether long-term lamotrigine administration aﬀected the re-
sponses to aversive and positive stimuli, and speciﬁcally reinstated the motivation
to operate for a natural reward in a rat model of depression. To this end, we used
a well-validated model of depressive behaviors induced by exposure to an unavoid-
able chronic stress protocol, that is characterized by decreased reactivity to aversive
stimuli (escape deﬁcit) and reduced motivation to operate to earn a palatable food,
sucrose (motivational anhedonia) [34, 35]. Motivational anhedonia, assessed in
rats by sucrose self-administration, is accompanied by decreased dopaminergic re-
sponses to a natural reward (sucrose) in the shell of the NAc (NAcS) [35]. The dopa-
minergic responses are assessed by analyzing the levels of extraneuronal dopamine
and measuring the dopamine D1 receptor-dependent signaling, in terms of cAMP-
dependent protein kinase (PKA)-dependent phosphorylation of the threonine (Thr)
34 residue of dopamine and cAMP-regulated phosphoprotein Mr 32,000
(DARPP-32) [36]. Pharmacological treatments that reinstate motivation to operate
for a natural reinforcer in self-administration protocols (lithium, imipramine, cloza-
pine, aripiprazole, and fenoﬁbrate), also restore the dopaminergic response to su-
crose consumption in the NAcS of stress-exposed rats, regardless of the acute
molecular mechanism [35, 37, 38, 39]. Thus, considering the reported eﬀects of la-
motrigine on the VTA dopaminergic neurons projecting to the NAc [27], we inves-
tigated whether repeated lamotrigine treatment could reverse the stress-inducedon.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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evaluated in terms of Thr34 DARPP-32 phosphorylation levels in the NAcS. More-
over, the study aimed to further validate the hypothesis that the re-established dopa-
minergic response to sucrose is accompanied by a restored motivation to operate for
the reward disrupted by stress exposure, using a sucrose self administration protocol
[35, 37, 38, 39]. The results of this study may have a translational value as they could
suggest possible clinical uses of lamotrigine to address speciﬁc symptoms in unipo-
lar or bipolar depression, in particular the symptom domain of motivational
anhedonia.2. Materials and methods
2.1. Animals
Experiments were carried out on male Sprague-Dawley rats (Charles River, Calco,
Italy), 9e10 week old and the experimental procedures began after 10 days of habit-
uation to the animal colony. Rats were housed in stable social groups of 4e5 animals
per cage (bedding Lignocel 3/4S, Harlan Laboratories, San Pietro al Natisone,
Italy) in a room maintained at constant temperature and humidity, on a 12 h reverse
light/dark cycle (lights on from 7 am to 7 pm) with free access to food (4RF21, Mu-
cedola, Settimo Milanese, Italy) and water. All rats were manipulated daily by exper-
imenters. Locomotor activity tests, escape tests and sucrose self-administration
protocols were performed between 9 and 12 am under red light and controlled noise
conditions, while stress exposure was carried out between 3 and 4 pm. The proced-
ures used were in compliance with the European legislation on the use and care of
laboratory animals (EU Directive 2010/63) and the guidelines issued by the National
Institutes of Health, and were approved by the University of Siena Ethics Commit-
tee. All eﬀorts were made to minimize the number of animals used and their
suﬀering.2.2. Acute escape deﬁcit induction and chronic stress protocol
Acute escape deﬁcit was induced by exposure to an unavoidable stress session (pre-
test) [34, 40]. Rats, immobilized with a ﬂexible wire-net, were administered 80 tail
shocks (1 mA  5 s, 1 every 30 s) in 50 min and 24 h later they were exposed to a
shock-escape test. The escape deﬁcit criterion was an escape number from 0 to 6 in
30 trials.
The condition of escape deﬁcit was chronically maintained by repeated exposure to
minor unavoidable stressors (10 min tail-shocks or restraint) on alternate days, as
described [34]. Rats were restrained by immobilizing them in a ﬂexible wire net
for 10 min. Exposure to unavoidable stress sessions were performed 3e4 h after
the end of self-administration sessions.on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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Locomotor activity was measured as previously described in an apparatus (Ime-
tronic, Pessac, France), composed of eight compartments, each of them equipped
with a transparent Perspex motility cage (23  33  19 cm) and a system of photo-
cell beams that detected horizontal and vertical activity [41]. On the test day rats
were placed in motility cages for 35 min and total motility counts were recorded
in the last 30 min.2.4. Self-administration procedure
Responding for sucrose was performed in rat operant chambers equipped with two
retractable levers (MED Associates Inc., St. Albans, VT, USA). Pressing on active
lever delivered a sucrose pellet (Bio-Serv, Frenchtown, NJ, USA) into the food recep-
tacle, while pressing on the inactive lever had no programmed consequences [35].
Experimental events and data collection were scheduled using MED Associates soft-
ware (MEDAssociates Inc.). Experiments were carried out daily between 9 and 12 am
in 30-min sessions in non food-deprived rats that had free access to food and water in
the home cage before and after each session. Rats were exposed to a ﬁxed-ratio 1
(FR1) schedule until the control group reached a criterion of 50 lever presses for 2
consecutive days, then they were switched to a ﬁxed ratio 5 (FR5) schedule. When
the control group reached a criterion of 40 responses, rats were switched to a progres-
sive ratio (PR) schedule, in which the number of responses required to receive a su-
crose pellet was progressively increased with a step size of 3 until 5 min had
elapsed without a response (breaking point, BP). BP was deﬁned as the number of
lever presses in the ﬁnal completed ratio. The criterion for a deﬁcit in appetitive moti-
vation, induced by exposure to the chronic stress protocol, was a lever-pressing rate
lower than 60% of the control group rate in FR1 and FR5 schedules [37].2.5. Immunoblotting
NAcS was identiﬁed using the Rat Brain Atlas as corresponding to plates 10e12 [42]
and excised using rapid head-freeze technique [38, 43]. Tissues were solubilized in
boiling 1% sodium dodecyl sulfate (SDS) and 50 mM NaF, and protein content
was determined by a modiﬁed Lowry protein assay method (DC protein assay,
Bio-Rad Laboratories, Hercules, CA, USA). Western blot analysis was performed
as previously described [44, 45]. Brieﬂy, proteins (30 mg) were resolved into 10%
SDSePAGE gels and electro-transferred onto nitrocellulose membranes. Membranes
were incubated with anti-phospho-Thr34 DARPP-32 (Thr34), anti-DARPP-32 (Cell
Signaling Technology, Beverly, MA, USA) and anti-b-actin antibodies. To control
for equal loading, membranes incubated with anti-DARPP-32 were stripped and re-
probed with anti-b-actin, and membranes incubated with anti-phospho-Thr34
DARPP-32 were stripped and reprobed with anti-DARPP-32 antibody. Detectionon.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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Inc., Rockford, IL, USA) and quantiﬁed with the Versa Doc 1000 Imaging System
(Bio-Rad Laboratories). Total DARPP-32 levels were normalized to those of b-actin,
phospho-protein levels were normalized to those of DARPP-32.2.6. Drugs and chemicals
Lamotrigine (Shreeji Pharma International, Vadodara, India) was dissolved in 0.5%
methylcellulose and 0.4% Tween 80 in deionized/distilled water and administered at
the dose of 7.5 mg/kg i.p. twice a day or 15 mg/kg i.p. twice a day [16, 18]. Rats in
the control groups received vehicle (0.5% methylcellulose and 0.4% Tween 80 in de-
ionized/distilled water). All treatments were administered in a volume of 1 ml/kg
body weight. All other chemicals were purchased from commercial sources.2.7. Statistical analysis
Statistical analyses were performed on commercially available software (GraphPad
Prism statistical package, GraphPad, San Diego, CA, USA). Diﬀerences between
two groups were determined by unpaired Student’s t-test. Self-administration exper-
iment data (FR1 and FR5) were analyzed by 2-way repeated measures analysis of
variance (RM ANOVA) with group as main factor and sessions as repeated factor.
BP results and escape numbers were analyzed using one-way ANOVA or two-way
ANOVA, as appropriate. Data on DARPP-32 phosphorylation levels after sucrose
consumption were analyzed by two-way ANOVA. Post-hoc analyses were per-
formed by the Bonferroni’s test, when p < 0.05.3. Experimental
3.1. Lamotrigine eﬀects on reactivity to aversive stimuli
a) Response to acute avoidable stress. First we investigated whether repeated lamo-
trigine administration impaired the escape response to avoidable aversive stimuli.
Rats, divided into 3 groups, were tested for escape without exposure to the un-
avoidable stress session: one group received the vehicle (1 ml/kg i. p. twice a
day, Naive vehicle group, n ¼ 6); one group received lamotrigine, 7.5 mg/kg i.
p. twice a day (LTG 7.5 group, n ¼ 8); one group received lamotrigine, 15 mg/
kg i. p. twice a day (LTG 15 group, n ¼ 8; Table 1). Lamotrigine or vehicle
were administered for 14 days. In order to evaluate whether lamotrigine treatment,
at the dose and regimen used, modiﬁedmotility, and thus confounded the results of
escape tests, locomotor activity was evaluated 24 h before the escape test.
b) Prevention of the consequences of acute stress exposure. We then investigated
whether a 14-day lamotrigine administration prevented the acute consequenceson.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 1. Outline of experimental protocols.
Experiment Experimental groups n Treatment Test
Acute avoidable stress Vehicle Naive 6 Vehicle 1 ml/kg i. p. twice a day for
14 days
Escape test
LTG 7.5 8 Lamotrigine 7.5 mg/kg i. p. twice a
day for 14 days
Escape test
LTG 15 8 Lamotrigine 15 mg/kg i. p. twice a
day for 14 days
Escape test
Prevention Vehicle Naive 6 Vehicle 1 ml/kg i. p. twice a day for
14 days
Escape test
Vehicle þ Acute Stress 6 Vehicle 1 ml/kg i. p. twice a day for
14 days
Pre-test and escape test
LTG Naive 6 Lamotrigine 7.5 mg/kg i.p. twice a
day for 14 days
Escape test
LTG þ Acute Stress 6 Lamotrigine 7.5 mg/kg i.p. twice a
day for 14 days
Pre-test and escape test
Reversal Vehicle Naive 6 Vehicle 1 ml/kg i. p. twice a day for
21 days
Escape test
Chronic Stress þ Vehicle 6 Chronic stress, Vehicle 1 ml/kg i. p.
twice a day for 21 days
Escape test
Chronic Stress þ LTG 8 Chronic stress, lamotrigine 7.5 mg/kg
i.p. twice a day for 21 days
Escape test
Performance in
sucrose SA
Vehicle 5 Vehicle 1 ml/kg i. p. twice a day for
21 days
Sucrose self-administration
(FR1, FR5, PR)
LTG 6 Lamotrigine 7.5 mg/kg i. p. twice a
day for 21 days
Eﬀect on motivational
anhedonia
Vehicle 8 Vehicle 1 ml/kg i. p. twice a day for
21 days
Chronic Stress þ Vehicle 8 Chronic stress, Vehicle 1 ml/kg i. p.
twice a day for 21 days
Sucrose self-administration
(FR1, FR5, PR)
Chronic Stress þ LTG 8 Chronic stress, lamotrigine 7.5 mg/kg
i.p. twice a day for 21 days
Phosphorylation levels
of THR34-DARPP-32
in the NACS
Vehicle 12 Vehicle 1 ml/kg i. p. twice a day for
14 days
Immunoblotting
Chronic Stress þ Vehicle 12 Chronic stress, vehicle 1 ml/kg i. p.
twice a day for 14 days
LTG 12 Lamotrigine 7.5 mg/kg i. p. twice a
day for 14 days
Every group was sacriﬁced
at baseline or after sucrose
consumption
Chronic Stress þ LTG 12 Chronic stress, lamotrigine 7.5 mg/kg
i. p. twice a day for 14 days
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group received the vehicle (1 ml/kg i. p., twice a day) and was exposed to the
escape test without exposure to the unavoidable stress session (Naive vehicle
group, n ¼ 6); one group received the vehicle (1 ml/kg i. p., twice a day),
was exposed to the unavoidable stress session and 24 h later to the escape test
(Vehicle þ Acute Stress group, n ¼ 6); one group received lamotrigine (7.5
mg/kg i. p. twice a day) and was exposed to the escape test without exposure
to the unavoidable stress session (LTG Naive, n ¼ 6); one group received lamo-
trigine (7.5 mg/kg i. p. twice a day), was exposed to the unavoidable stress ses-
sion and 24 h later to the escape test (LTGþ Acute Stress group, n¼ 6; Table 1).on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 1. Lamotrigine reinstated the reactivity to aversive stimuli. (a, b) A 14-day lamotrigine treatment at
the dose of 7.5 mg/kg twice a day did not modify the competence to escape avoidable aversive stimuli,
while at the dose of 15 mg/kg twice a day reduced avoidable stress reactivity. Rats, divided into 3 groups,
received vehicle (1 ml/kg, i. p.) or lamotrigine 7.5 mg/kg (LTG 7.5) or 15 mg/kg i. p. (LTG 15), twice a
day. After 14 days, rats were tested for escape without exposure to the unavoidable stress session. (c, d)
A 14-day lamotrigine administration prevented the development of stress-induced escape deﬁcit. As out-
lined in (c), two groups of rats were administered vehicle or lamotrigine 7.5 mg/kg i. p. twice a day for 14
days. Then they were exposed to unavoidable stress (Vehicle þ Acute Stress and LTG þ Acute Stress)
and 24 h later to the escape test, or they were tested for escape without unavoidable stress exposure
(Vehicle Naive and LTG Naive). (e, f) Lamotrigine repeated treatment reverted the condition of escape
deﬁcit induced by chronic stress exposure. As outlined in (e), two groups of rats were exposed to un-
avoidable stress session and 24 h later they were tested for escapes. Four-ﬁve hours later, they began
treatment with vehicle (Chronic Stress þ Vehicle), or lamotrigine 7.5 mg/kg i. p. twice a day (Chronic
Stress þ LTG) for 3 weeks, concomitantly with exposure to the stress protocol. The Vehicle Naive group
received vehicle for 3 weeks, without stress exposure. At the end of 3 weeks, all rats were tested for
escape. Scores are expressed as mean  S.E.M. of escape numbers in 30 consecutive trials. *p <
0.05, ***p < 0.001 versus the other groups (post hoc Bonferroni’s test).
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uate the possible antidepressant-like activity of lamotrigine, we examined
whether a repeated treatment reverted the escape deﬁcit induced by exposure
to unavoidable stress and maintained by the chronic stress protocol (as outlined
in Fig. 1e). To this end, 20 rats were divided into 3 groups: vehicle-treated con-
trol rats (1 ml/kg i. p., twice a day) never exposed to stressors (Vehicle Naive, n
¼ 6); vehicle-treated rats (1 ml/kg i. p., twice a day) ﬁrst exposed to the pre-test
and escape test sequence, and then to the 21-day chronic stress protocolon.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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a day) ﬁrst exposed to the pre-test and escape test sequence, and then to the 21-
day chronic stress protocol (Chronic Stress þ LTG, n ¼ 8; Table 1). Treatments
began on day 2 after the Chronic Stress þ Vehicle and Chronic Stress þ LTG
groups had been exposed to the escape test and continued for the 3 weeks of
exposure to the stress protocol. Rats were then tested for escape, 18 h after
the last treatment and stressor exposure.3.2. Lamotrigine eﬀects on performance in sucrose self-
administration protocols
a) Eﬀect of lamotrigine administration on sucrose self-administration. A prelimi-
nary experiment was carried out to verify that repeated lamotrigine administra-
tion did not aﬀect the performance in sucrose self-administration schedules. Rats
received vehicle (1 ml/kg i. p., twice a day, Vehicle, n ¼ 5) or lamotrigine (7.5
mg/kg i. p. twice a day, LTG, n ¼ 6) for 8 days, Table 1; then, they began the
self-administration training while continuing treatment. When rats attained
consistent responding in FR1 and FR5, the schedule of reinforcement was
changed to a PR with a step size of three.
b) Lamotrigine eﬀects on stress-induced motivational anhedonia. Rats were
divided into a control group (CTR, n ¼ 8) and a group exposed to the sequence
of unavoidable stress-escape test (day 1 and 2) and then to the chronic stress
protocol (Chronic Stress, n ¼ 16) (Fig. 3a). At day 10 self-administration
training began under FR1 and FR5 schedules. When the chronic stress group
attained the criterion for appetitive motivation deﬁcit, rats were allocated in
two diﬀerent subgroups, one treated with vehicle (1 ml/kg/day, i. p., twice a
day, Chronic Stress þ Vehicle, n ¼ 8) and the other with lamotrigine (7.5
mg/kg, i. p., twice a day, Chronic Stress þ LTG, n ¼ 8) (day 21), while
continuing to be exposed to the stress protocol. The CTR group received the
vehicle (1 ml/kg/day, i. p., twice a day, Vehicle, n ¼ 8; Table 1) (Fig. 3a).
On the 8th treatment day (day 28), self -administration training with an FR5
schedule was resumed for 6 sessions, then rats were switched to a PR schedule
with a step size of three (14th treatment day, Fig. 3a).3.3. Lamotrigine eﬀects on phosphorylation levels of Thr34-
DARPP-32 in the NAcS of rats exposed to the chronic stress
protocol
In order to study whether repeated lamotrigine administration restored the DARPP-
32 response to sucrose, in rats exposed to chronic stress and administeredon.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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by immunoblotting at baseline and after the consumption of a 10% sucrose solution.
Forty-eight rats were divided into Control (CTR, n ¼ 24) and Chronic Stress (n ¼
24) groups. Rats in the Chronic Stress group were exposed to the sequence of pretest
and escape test (day 1 and 2) and then to the stress protocol until the end of the exper-
iment (Fig. 4a). From day 21 half of the animals in the Control and Chronic Stress
groups received the vehicle (1 ml/kg/day i. p. twice a day, Vehicle, n ¼ 12; Chronic
Stressþ Vehicle, n¼ 12), and half of the animals received lamotrigine (7.5 mg/kg i.
p. twice a day, LTG, n ¼ 12; Chronic Stress þ LTG, n ¼ 12; Table 1), (Fig. 4a).
During the last week of treatment, all rats were habituated to receive an oral admin-
istration of 500 ml of water. After 14 days of treatment, 6 rats in each subgroup were
sacriﬁced at baseline and the other 6 rats were sacriﬁced 30 min after oral adminis-
tration of 500 ml of a 10% sucrose solution.4. Results
4.1. Eﬀects of repeated lamotrigine administration on the
reactivity to aversive stimuli
Repeated lamotrigine administration at the dose of 7.5 or 15 mg/kg i. p. twice a day
did not modify locomotor activity (motility counts: Vehicle ¼ 50.50  10.75; LTG
7.5 ¼ 42.00  8.8; LTG 15 ¼ 35.13  5.2; one-way ANOVA, F2,19 ¼ 0.821, p ¼
0.45). Moreover, the competence to escape avoidable aversive stimuli was not modi-
ﬁed by a 14-day lamotrigine treatment at the dose of 7.5 mg/kg i. p. twice a day,
while at the dose of 15 mg/kg i. p. twice a day, lamotrigine reduced avoidable stress
reactivity (one-way ANOVA, F2,19 ¼ 6.72, p < 0.01; Fig. 1a,b). Post hoc analysis
demonstrated that the LTG 15 group showed a number of escapes lower than the
LTG 7.5 or Vehicle Naive groups (p < 0.05, both comparisons). Thus, a dose of la-
motrigine of of 7.5 mg/kg twice a day was used in the following experiments.
We then investigated whether a 14-day lamotrigine administration prevented the
acute consequences of unavoidable stress exposure (Fig. 1c). Analysis of the number
of escapes by two-way ANOVA showed a signiﬁcant eﬀect of stress (F1,120¼ 39.95,
p < 0.001), treatment (F1,20 ¼ 22.79, p < 0.001), and their interaction (F1,20 ¼
28.42, p< 0.001). Post hoc comparisons revealed that acute stress exposure induced
a clear-cut escape deﬁcit, while lamotrigine treatment prevented this deﬁcit (Vehicle
þ Acute Stress group versus Vehicle Naive, LTG Naive and LTG þ Acute Stress
groups: p < 0.001, Fig. 1d).
Next, in order to evaluate the possible antidepressant-like activity of lamotrigine, we
used a more stringent criterion and examined whether a repeated treatment reverted
the escape deﬁcit induced by exposure to unavoidable stress and maintained by the
chronic stress protocol (as outlined in Fig. 1e). Lamotrigine treatment completelyon.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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0.001). In particular, post hoc analysis showed that the Chronic Stress group ex-
hibited a clear condition of escape deﬁcit in comparison to the Naive and Chronic
Stress þ LTG groups (Chronic Stress group versus Naive and Chronic Stress þ
LTG groups: p < 0.001, Fig. 1f).4.2. Eﬀects of repeated lamotrigine administration on
performance in sucrose self-administration protocols
A preliminary experiment was carried out to verify that repeated lamotrigine admin-
istration did not aﬀect the acquisition of an operant behavior maintained by sucrose,
a natural reward. Lamotrigine administration did not modify the ability to acquire
sucrose self-administration as the only factor that aﬀected the performance was
the training session (twoeway RM ANOVA: FR1: treatment F1,9 ¼ 0.019, p ¼
0.89, training session F5,45 ¼ 12.25, p < 0.001, interaction F5,45 ¼ 0.42, p ¼
0.83; FR5: treatment F1,9 ¼ 0.35, p ¼ 0.56, training session F4,36 ¼ 10.15, p <
0.001, interaction F4,36 ¼ 0.20, p ¼ 0.93; PR: unpaired Student’s t test, p ¼ 0.37;
Fig. 2).
Next, to further study the antidepressant-like eﬀects of lamotrigine, we examined
whether lamotrigine treatment was able to reinstate the motivation to operate in a su-
crose self-administration protocol impaired by chronic stress exposure (Fig. 3a). As
expected, the chronic stress protocol aﬀected the acquisition of sucrose self-
administration [two-way RM ANOVA, stress (FR1: F1,22 ¼ 25.10, p < 0.001;Fig. 2. Lamotrigine per se did not aﬀect sucrose self-administration. As outlined in (a), rats were admin-
istered lamotrigine 7.5 mg/kg i. p. (LTG) or vehicle (Vehicle) twice a day for 8 days and they were then
trained to lever press for sucrose under Fixed Ratio 1 (FR1) schedule (b), while continuing treatments.
When stable responses under Fixed Ratio 5 (FR5) schedule (c) were obtained, rats were switched to a
Progressive Ratio (PR) schedule (d) with a step size of three. Data are presented as mean  S.E.M.
on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 3. Lamotrigine counteracted stress-induced motivational anhedonia and escape deﬁcit. As outlined
in (a), rats, exposed to the chronic stress protocol (Chronic Stress) or not exposed (CTR), were trained for
sucrose self-administration and when motivational anhedonia was established (c), rats in the Chronic
Stress group started to receive vehicle (Chronic Stress þ Vehicle) or lamotrigine (7.5 mg/kg i. p.,
Chronic Stress þ LTG) twice a day. After 8 days of treatment (day 28), they resumed the FR5 schedule
(d) and at the 14th day of treatment were shifted to the PR schedule (e), while continuing treatment and
stress exposure. (f) 24 h after the last PR session, rats were tested for escape. Scores are expressed as
mean  S.E.M. of escape numbers in 30 consecutive trials. (b, c) *p < 0.05, ***p < 0.001, Chronic
Stress group versus CTR group; (d) *p < 0.05, **p < 0.01, ***p < 0.001, Chronic Stress þ Vehicle
group versus Vehicle group; zp < 0.05, Chronic Stress þ LTG group versus Vehicle group; yyp <
0.01, yyyp < 0.001, Chronic Stress þ LTG group versus Chronic Stress þ Vehicle group (post hoc Bon-
ferroni’s test).
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¼ 7.256, p < 0.001), and their interaction (FR1: F4,88¼ 8.25, p < 0.001; FR5: F4,88
¼ 5.76, p < 0.001)]. Post hoc analysis showed that exposure to the chronic stress
protocol impaired the acquisition of operant responding in FR1 (Chronic Stress
versus CTR group: p < 0.05, session 2; p < 0.001, sessions 3, 4 and 5) and FR5
(Chronic Stress versus CTR group: p < 0.001, all sessions) (Fig. 3b,c).
After 8 days of lamotrigine treatment, self-administration sessions were resumed un-
der FR5 schedule. Lamotrigine treatment completely restored the competence to ac-
quire sucrose self-administration, thus counteracting the eﬀects of stress (two-way
RM ANOVA; group: F2,21 ¼ 9.57, p < 0.01; session: F5,105 ¼ 22.31, p < 0.001;on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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the reduced performance in sucrose self-administration induced by stress exposure
(Chronic Stressþ Vehicle versus Vehicle group, p< 0.05, sessions 1; p< 0.01, ses-
sions 2 and 4; p< 0.001, sessions 3, 5 and 6) was completely rescued by lamotrigine
treatment (Chronic Stressþ LTG group versus Chronic Stressþ Vehicle group: p<
0.01, session 5; p < 0.001, session 6, Fig. 3d). Moreover, analysis of the BP under
the PR schedule conﬁrmed that chronic stress exposure impaired operant responding
for sucrose, thus reducing the motivation to operate for a reward and lamotrigine
treatment restored the incentive motivation in stressed rats (one-way ANOVA:
F2,21 ¼ 18.73, p < 0.001; post hoc test: Chronic Stress þ Vehicle versus Vehicle
group, p < 0.01; Chronic Stress þ LTG versus Chronic Stress þ Vehicle group,
p < 0.001, Fig. 3e). In this experiment rats underwent stress exposure for 42
days. Thus, to verify whether lamotrigine administration restored reactivity to aver-
sive stimuli after prolonged exposure to the stress protocol, rats in each group were
tested for escape 24 h after the end of self-administration experiments. The number
of escapes was diﬀerent between groups (one-way ANOVA, F2,21 ¼ 67.49, p <
0.001) and post hoc analysis demonstrated a clear-cut escape deﬁcit in the Chronic
Stress þ Vehicle group, while the Chronic Stress þ LTG group showed a perfor-
mance similar to that of the Vehicle group (Fig. 3f).4.3. Eﬀects of repeated lamotrigine administration on
phosphorylation levels of Thr34-DARPP-32 in the NAcS of rats
exposed to the chronic stress protocol
In order to study the dopaminergic response to a natural reinforcer in the NAcS,
Thr34-DARPP-32 phosphorylation levels were analyzed by immunoblotting after
oral administration of a 10% sucrose solution to rats in the diﬀerent experimental
groups. Levels of total DARPP-32 in the NAcS were similar in the four experimental
groups (one-way ANOVA, F3,20 ¼ 0.63, p ¼ 0.60, Fig. 4b). Lamotrigine adminis-
tration reinstated the DARPP-32 phosphorylation changes in the NAcS in response
to acute sucrose consumption disrupted by stress exposure. Analysis by two-way
ANOVA of Th34-DARPP-32 phosphorylation levels expressed as percentage of
the baseline values of Vehicle group (rats not exposed to sucrose consumption) re-
vealed a signiﬁcant eﬀect of group (F3,40 ¼ 4.28, p < 0.05), sucrose consumption
(F1,40 ¼ 27.06, p < 0.001), and their interaction (F3,40 ¼ 2.99, p < 0.05). Baseline
levels of phospho-Thr34 DARPP-32 were similar between groups (Fig. 4c). Chronic
stress exposure impaired the increase in phospho-Thr34 DARPP-32 levels in
response to sucrose exhibited by control animals (Chronic Stress þ Vehicle versus
Vehicle group, p < 0.001), while lamotrigine administration restored the Thr34-
DARPP-32 response to a natural reinforcer (Chronic Stress þ Vehicle versus
LTG and Chronic Stress þ LTG groups, p < 0.01, Fig. 4c; original images are
shown in the supplementary material).on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 4. Lamotrigine reinstated the dopaminergic response to sucrose impaired by stress exposure in the
NAcS. As outlined in (a), rats in the Chronic Stress group were exposed to the stress protocol for 3
weeks. On day 21, part of the Control and Chronic Stress rats continued to receive the vehicle (Vehicle
and Chronic Stress þ Vehicle groups), while the remaining rats were administered lamotrigine (7.5 mg/
kg i. p., LTG and Chronic Stress þ LTG groups), twice a day. (b) DARPP-32 levels were normalized to
their respective b-actin levels and data are expressed as mean  S.E.M. of percentage modiﬁcations
compared those of the Vehicle group. (c) Phospho-Thr34 DARPP-32 levels were normalized to the
respective DARPP-32 levels and data are expressed as mean  S.E.M. of percentage modiﬁcations
compared to those of the baseline (- sucrose) Vehicle group levels. **p < 0.01, ***p < 0.001, versus
the Chronic Stress þ Vehicle (þ sucrose) group (post hoc Bonferroni’s test).
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Repeated lamotrigine administration prevented and relieved the stress-induced hy-
poreactivity to negative aversive stimuli (that is, escape deﬁcit) and reinstated the
physiological response to natural rewarding stimuli (sucrose) in a stress-induced
depressive-like phenotype in rats. The pro-motivational eﬀect of repeated lamotri-
gine administration that we observed in stress-exposed “anhedonic” rats is a novel
ﬁnding since only the consummatory component of reduced responses to pleasur-
able stimuli has been previously investigated in animal models [18]. In our experi-
mental conditions appetitive motivational anhedonia is closely linked to reduced
dopaminergic responses to sucrose, evaluated in terms of increases in extraneuronal
dopamine levels in the NAcS of non food-deprived rats [35]. Indeed, modiﬁcations
in dopamine D1 receptor-dependent signaling in the NAcS after sucrose consump-
tion, measured as PKA-dependent phosphorylation of Thr34 DARPP-32, positively
correlate with changes reported in extraneuronal dopamine levels [35, 46, 47].
Repeated pharmacological treatments that counteract these blunted dopaminergic re-
sponses to a natural reinforcer reestablish the motivation to operate for a reward, as
indicated by PR and BP values in sucrose self-administration [35, 37, 38]. The pre-
sent results show that repeated lamotrigine treatment was able to reinstate the PKA-on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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in the NAcS of non-food-deprived rats. Conﬁrming our working hypothesis, the ef-
fect on dopaminergic transmission was accompanied by the reinstated behavioral
response to a positive stimulus, in agreement with our previous studies [35, 37,
38, 39]. The role of the dopamine D1 receptor pathway in the NAc in hedonic/anhe-
donic behaviors has also been demonstrated in a rat model of bipolar disorder [48].
Moreover, the eﬀects of repeated lamotrigine administration that we report may be
interpreted in the frame of data indicating modulation by this drug of VTA dopami-
nergic neurons activity and resulting dopaminergic responses in the NAcS [27].
Consistent with previous observations [35], chronic unavoidable stress exposure
impaired the reactivity to noxious stimuli and motivation to operate for natural
reinforcer. Also, it disrupted the dopaminergic response in the NAcS elicited by
the intake of a natural reward in non-food-deprived rats. In rats, the stress-
induced escape deﬁcit and the impaired acquisition of an operant behavior main-
tained by salient rewarding stimuli represent a good translational model that mimic
the increased negative aﬀect and the decreased positive aﬀect [34, 35, 49] that have
been described in depressed patients [50, 51]. These two deﬁcits induced by
chronic unavoidable stress exposure are diﬀerently aﬀected by classical antidepres-
sants. In the model used, the escape deﬁcit is completely reverted by a long-term
treatment (w3 weeks) with antidepressant drugs, such as imipramine, ﬂuoxetine,
reboxetine, mirtazapine [34, 37, 52, 53], while motivational anhedonia is only
partially reverted by imipramine and unaﬀected by ﬂuoxetine treatment [37]. On
the other hand, the deﬁcit in appetitive motivation is completely counteracted by
lithium, clozapine, aripiprazole, and fenoﬁbrate long-term administration [35, 37,
38, 39]. It is interesting to note that lamotrigine, lithium, and aripiprazole that in
our experimental model restored the responses to a natural reward are among
the drugs that have been approved by FDA for maintenance treatment of bipolar
disorder.
In this study, a 14-day lamotrigine treatment was eﬀective in the prevention of
escape deﬁcit development elicited by exposure to acute inescapable stress, and a
21-day lamotrigine treatment rescued the condition of escape deﬁcit maintained
by the long-term stress protocol, similar to what antidepressant drugs do on this
test [34, 52, 53]. Our ﬁndings are consistent with previously published studies
that demonstrate antidepressant-like eﬀects of repeated lamotrigine administration
on reactivity to aversive stimuli [16, 17, 18], or positive stimuli, e.g., sucrose in
the sucrose preference test [18]. Diﬀerently from previous ﬁndings [16, 18], in
our experimental conditions lamotrigine was eﬀective on the stress-induced deﬁcits
at the dose of 7.5 mg/kg/twice a day, while the dose of 15 mg/kg/twice a day
decreased the escape response, an eﬀect likely related to the slight impairment
observed in locomotor activity.on.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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anhedonia [54, 55] and dopamine signaling in the NAc has been identiﬁed as playing
an important role in the regulation of eﬀort-related and activational aspects of moti-
vation [56]. Burst ﬁring of VTA dopaminergic neurons and the subsequent phasic
dopamine release in the NAc encodes the occurrence and the valence of salient stim-
uli [57, 58], playing an important role in motivated behavior [59]. Moreover, chemo-
genetic activation of VTA dopaminergic neurons results in an increased responding
for sucrose in a PR schedule of reinforcement, that is, it enhances incentive motiva-
tion [60]. VTA dopaminergic neurons that project to the NAcS exhibit a large
hyperpolarization-activated inward current, Ih, that modulates their electrophysio-
logical properties and ﬁring rate [61]. This current that modulates VTA ﬁring activ-
ity seems to be crucial for the formation of cue-reward association and motivated
behaviors [27, 61]. Lamotrigine is an enhancer of Ih currents [26] and its antidepres-
sant eﬀects may be related to the inﬂuence on VTA dopaminergic neurons ﬁring ac-
tivity. In a model of chronic social defeat stress, lamotrigine, repeatedly infused in
the VTA of the susceptible subpopulation of defeated mice, reverts social avoidance
and sucrose preference deﬁcit. In susceptible mice VTA dopaminergic neurons pro-
jecting to the NAc show enhanced ﬁring rates that are normalized following
lamotrigine-induced sustained Ih current potentiation [27]. These data suggest that
the anti-anhedonic-like eﬀects of repeated lamotrigine administration could correlate
with its ability to normalize the ﬁring rate of VTA dopaminergic neurons modiﬁed
by stress exposure. Actually, the results on the PKA-dopamine D1 receptor-DARPP-
32 response to sucrose in the NAcS are consistent with the hypothesis that lamotri-
gine modulation of VTA dopaminergic neurons activity and the resulting dopami-
nergic responses in the NAc underlies the eﬀects on motivational anhedonia and
depressive-like behaviors.
The results obtained in our experimental model of depressive-like symptoms seem to
correlate with the alleged clinical eﬃcacy of lamotrigine in bipolar depression. The
pro-motivational activity of lamotrigine that we report may have a counterpart in the
proposed eﬃcacy of this drug as augmentation therapy for patients with treatment
resistant depression [62, 63, 64], although a clear impact on the anhedonic domain
has not been clearly assessed and demonstrated in clinical studies.
In our experimental conditions, lamotrigine eﬀects diﬀer from those observed after
administration of aripiprazole, a second generation antipsychotic also used as add-on
therapy in the treatment of bipolar disorder and treatment-resistant depression. Ari-
piprazole diﬀerently modulates the responses to aversive and rewarding stimuli,
since it restores the motivation to operate for, and the dopaminergic response to, pos-
itive stimuli (sucrose), without aﬀecting stress-induced decreased reactivity to aver-
sive stimuli, conﬁrming that motivations to operate for a reward or to avoid negative
stimuli could be dissociated [39]. Thus, experimental models of depressive symp-
toms suggest that diﬀerent drugs used for the treatment of mood disorderson.2018.e00849
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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fects of lithium and lamotrigine develop faster than those of classical antidepressants
[35, 37, 39]. These results on the antidepressant-like and pro-motivational activity of
lamotrigine in an animal model are endowed with translational value as they could
suggest a clinical use of this drug to target the symptom domain of motivational
anhedonia in unipolar or bipolar depression.5.1. Limitations
The pro-motivational eﬀects of lamotrigine observed in our model may not fully
transpose to the patients, since anhedonia is a multidimensional construct and the
motivational aspects although relevant, are not the only components.6. Conclusions
This study demonstrates a clear pro-motivational eﬀect of repeated lamotrigine
administration, accompanied by a restored dopaminergic response in the NAcS,
possibly consequent to the modulation of VTA dopaminergic neurons ﬁring rate.
These data are suggestive of a correlation with the results of clinical studies where
early improvement in positive aﬀect has been shown to be predictive of antidepres-
sant treatment response [51, 65]. Thus, studies of drugs activity on diﬀerent behav-
ioral symptoms of mood disorders modeled in animals may support clinical choices
of pharmacological therapies oriented to treat prevalent symptom domains.Declarations
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